RI Hospital Study:
Graft Occlusion in Hemodialysis Patients
Rhode Island Hospital is seeking patients to participate in a phase
I trial with plasmin to evaluate the safety and to select the doses
of phase II in patients with hemodialysis graft occlusion.
Plasmin is a direct thrombolytic agent developed as a potential
therapeutic agent for the treatment of hemodialysis patients with
thrombosed arterio-venous shunts.
Patients or individuals interested in taking part in this trial
should be on chronic hemodialysis with a graft that now is occluded
or has gone down.
For more information, or to refer a patient, please contact
the vascular interventional radiology department at 401-444-5194.
Back
|
